Skip to main content
Premium Trial:

Request an Annual Quote

Henry Ford Health System, Catholic Health Initiatives Launch Precision Oncology Programs

NEW YORK (GenomeWeb) – The Henry Ford Health System and Catholic Health Initiatives will collaborate with Syapse to launch precision oncology programs and plan to join the Oncology Precision Network (OPeN) consortium to share cancer outcomes data with other health systems, they said today.

The OPeN consortium was launched earlier this month by Syapse, Intermountain Healthcare, Stanford Cancer Institute, and Providence Health & Services. The initiative aims to link and share aggregated clinical, molecular, and treatment data between its members using Syapse technology.

Also today, Syapse said that OPeN would add three more health system members by the end of the year in support of Vice President Biden's Cancer Moonshot Initiative.

As part of its precision oncology program, Henry Ford Health System will open a new $110 million cancer center in Detroit in 2018, as well as implement Syapse's Precision Medicine Platform software throughout its cancer care facilities, including the Henry Ford Hospital in Detroit.

"The Precision Medicine Program and partnership with Syapse, coupled with the creation of our new Detroit cancer center, solidifies our unwavering commitment to our patients in Detroit and beyond to continuously advance cancer clinical care, research, and innovation," John Popovich, president and CEO of Henry Ford Hospital, said in a statement.

Catholic Health Initiatives also plans to implement Syapse's Precision Medicine Platform software in its cancer care facilities. CHI operates 103 hospitals across 18 states.

"Our partnership with Syapse will allow us to scale precision medicine beyond academic medical centers, and into the community hospitals that serve a vast majority of the nation’s cancer patients," Dax Kurbegov, system vice president of CHI's national oncology service line, said in a statement, adding that the alliance will enable CHI to "deliver precision medicine to patients at unprecedented scale."